Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2007

01-11-2007 | Concise Article

The anti-cancer effects of quinolone antibiotics?

Authors: M. Paul, A. Gafter-Gvili, A. Fraser, L. Leibovici

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2007

Login to get access

Abstract

A previous meta-analysis showed that quinolones administered for prophylaxis of infections among cancer patients reduced all-cause mortality. We extracted from the primary trials infection-related and all-cause mortality as reported and assessed the effect of quinolones on non-infection-related mortality through meta-analysis. Among trials comparing quinolones to placebo or no treatment, a significant reduction in non-infection-related mortality was observed (relative risk 0.54, 95% confidence interval 0.32–0.93, 15 trials, 3,320 patients). This finding might represent biased attribution of deaths to infection or might be compatible with an anti-cancer effect of quinolone antibiotics. We present further analyses addressing these possibilities.
Literature
1.
Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L (2005) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 4:CD004386PubMed
2.
Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995PubMed
3.
Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39(Suppl 1):S25–S31PubMedCrossRef
4.
Gerain J, Sculier JP, Malengreaux A, Rykaert C, Themelin L (1990) Causes of deaths in an oncologic intensive care unit: a clinical and pathological study of 34 autopsies. Eur J Cancer 26:377–381PubMed
5.
Santoso JT, Lee CM, Aronson J (2006) Discrepancy of death diagnosis in gynecology oncology. Gynecol Oncol 101:311–314PubMedCrossRef
6.
Di Furia L, Piga A, Marmili S, Breccia R, Rubini C, Beltrami CA, Mariuzzi GM, Cellerino R (1991) The value of necropsy in oncology. Eur J Cancer 27:559–561PubMedCrossRef
7.
8.
9.
Shalit I, Kletter Y, Weiss K, Gruss T, Fabian I (1997) Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Eur J Haematol 58:92–98PubMedCrossRef
10.
Riesbeck K, Forsgren A (1990) Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin. Eur J Clin Microbiol Infect Dis 9:409–413PubMedCrossRef
11.
Shalit I, Kletter Y, Halperin D, Waldman D, Vasserman E, Nagler A, Fabian I (2001) Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur J Haematol 66:287–296PubMedCrossRef
12.
Brodsky AL, Minissale CJ, Melero MJ, Sanchez Avalos JC (1993) Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (B Aires) 53:401–407
13.
Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRef
14.
Carlson JW, Fowler JM, Mitchell SK, Carson LF, Mayer AR, Copeland LJ (1997) Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Gynecol Oncol 65:325–329PubMedCrossRef
15.
Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998PubMedCrossRef
16.
Guiot HF, van den Broek PJ, van der Meer JW, van Furth R (1983) Selective antimicrobial modulation of the intestinal flora of patients with acute nonlymphocytic leukemia: a double-blind, placebo-controlled study. J Infect Dis 147:615–623PubMed
17.
Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Saral R, Burke PJ (1987) Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106:1–7PubMed
18.
Lalami Y, Paesmans M, Aoun M, Munoz-Bermeo R, Reuss K, Cherifi S, Alexopoulos CG, Klastersky J (2004) A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer 12:725–730PubMedCrossRef
19.
Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R (1991) Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 51:630–636PubMedCrossRef
20.
Moreau P, Milplied N, Richard P, Bulbois CE, Richet H, Harousseau JL (1995) Prospective randomized study comparing prophylactic ciprofloxacin (C) and amoxicillin + clavulanic acid (A-CA) vs prophylactic vancomycin (V) vs non prophylactic conventional empiric antimicrobial therapy in neutropenic patients [abstract]. Bone Marrow Transplantation 15(Suppl 2):129
21.
Nenova IS, Ananostev NH, Goranov SE, Mateva NG, Haidushka IA (2001) Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies. Folia Med (Plovdiv) 43:40–45
22.
Sampi K, Maseki N, Hattori M (1992) A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study. Gan To Kagaku Ryoho 19:823–826PubMed
23.
Schroeder M, Schadeck-Gressel C, Selbach J, Westerhausen M (1992) Antibiotic prophylaxis with gyrase inhibitors during cytostatically induced granulocytopenias in patients with solid tumors: A double-blind prospective randomized study. Onkologie 15:476–479CrossRef
24.
Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L (1993) Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother 37:474–482PubMed
25.
Thomas X, Troncy J, Belhabri A, Thiebaut A, Bouheddou N, Michallet M, Fleurette J, Pivot C, Fiere D, Archimbaud E (2000) Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study. Presse Med 29:1745–1751PubMed
26.
Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G (2001) Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368PubMedCrossRef
27.
Kamat AM, DeHaven JI, Lamm DL (1999) Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54:56–61PubMedCrossRef
28.
Kamat AM, Lamm DL (2004) Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63:457–460PubMedCrossRef
29.
Seay TM, Peretsman SJ, Dixon PS (1996) Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 155:757–762PubMedCrossRef
30.
Zehavi-Willner T, Shalit I (1992) The inhibitory effect of ciprofloxacin on proliferation of a murine bladder carcinoma cell line. J Antimicrob Chemother 29:323–328PubMedCrossRef
31.
Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T (1997) The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 80:2263–2267PubMedCrossRef
32.
Aranha O, Wood DP Jr, Sarkar FH (2000) Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 6:891–900PubMed
33.
Yamakuchi M, Nakata M, Kawahara K, Kitajima I, Maruyama I (1997) New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett 119:213–219PubMedCrossRef
34.
Somekh E, Douer D, Shaked N, Rubinstein E (1989) In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther 248:415–418PubMed
35.
Thadepalli H, Salem F, Chuah SK, Gollapudi S (2005) Antitumor activity of trovafloxacin in an animal model. In Vivo 19:269–276PubMed
36.
Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Nakano H (1992) Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 52:2818–2822PubMed
37.
Dohden K, Kaizaki Y, Hosokawa O, Hayashi H, Hattori M (2004) Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case. Dis Colon Rectum 47:1544–1546PubMed
38.
Hori K, Suguro M, Koizuka H, Sakagami T, Tomita T, Kosaka T, Fukuda Y (2004) Disappearance of rectal mucosa-associated lymphoid tissue lymphoma following antibiotic therapy. Dig Dis Sci 49:413–416PubMedCrossRef
39.
Huang D, Okada K, Komori C, Itoi E, Suzuki T (2004) Enhanced antitumor activity of ultrasonic irradiation in the presence of new quinolone antibiotics in vitro. Cancer Sci 95:845–849PubMedCrossRef
40.
Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE (1998) Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 16:509–512PubMedCrossRef
41.
Herold C, Ganslmayer M, Ocker M, Blauberger S, Zopf S, Hahn EG, Schuppan D (2003) Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. Int J Oncol 23:751–756PubMed
42.
Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH (2003) Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 22:787–794PubMed
Metadata
Title
The anti-cancer effects of quinolone antibiotics?
Authors
M. Paul
A. Gafter-Gvili
A. Fraser
L. Leibovici
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0375-4

Other articles of this Issue 11/2007

European Journal of Clinical Microbiology & Infectious Diseases 11/2007 Go to the issue

Brief Report

Candidemia complicated by endophthalmitis: a prospective analysis

Brief Report

Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia

Review

The cranberry and the urinary tract

Article

Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention

Letter to the Editor

Predictability of vancomycin pharmacokinetics in neonates

Case Report

Persistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits